



**VASCULITIS
CLINICAL
RESEARCH
CONSORTIUM**



The VCRC
**Longitudinal Study for
Microscopic
Polyangiitis
&
Wegener's
Granulomatosis**

What is a longitudinal study?

A longitudinal study follows patients over an extended period of time to look at changes in individuals. Information is collected on a regular basis and studied by research scientists to find new ways to track

disease and predict who will respond to different treatments, to study the genetics and causes of vasculitis, to understand how best to treat patients, and much more.

The Longitudinal Study is not a drug study but it may lead to development of new treatments.

Why participate?

By participating in the Longitudinal Study you will help researchers better understand Microscopic Polyangiitis and Wegener's Granulomatosis and work toward developing more effective and safer therapies.

What does this study involve?

If you are eligible and decide to participate in this study, you will be asked to come to a clinical center on a regular basis to meet with a physician, to answer medical questions, and to provide blood and urine samples. The study will last for several years.

Who qualifies?

You must have a confirmed diagnosis of Microscopic Polyangiitis or Wegener's Granulomatosis and be willing to be seen for study visits at one of the VCRC study sites.

What is a study visit?

During a study visit, you will meet with a study physician, a study coordinator, and a research nurse. Medical information will be collected and a physical exam conducted. The research nurse will collect blood and urine specimens from you. On some study visits, you will only have blood and urine collected and will not meet with the physician or study coordinator (these visits may be shorter).

Where will the study take place? How do I participate?

If you are interested in participating in this study or would like additional information, please contact a study coordinator at the clinical center most convenient for you:

**Boston University School of Medicine,
Boston, Massachusetts**

Study Coordinator: Zarabeth Golden,
E-mail: zgolden@bu.edu
Tel: 617-414-2507

Principal Investigator: Peter A. Merkel, MD, MPH

**Cleveland Clinic Foundation,
Cleveland, Ohio**

Study Coordinator: Katherine Tuthill,
E-mail: tuthillk@ccf.org
Tel: 216-444-9606

Principal Investigator: Carol A. Langford, MD, MHS

**Mayo Clinic College of Medicine,
Rochester, Minnesota**

Study Coordinator: Kathleen Mieras,
E-mail: mieras.kathleen@mayo.edu
Tel: 507-284-9187

Principal Investigator: Ulrich Specks, MD

**Johns Hopkins Vasculitis Center,
Baltimore, Maryland**

Study Coordinator: Cynthia Bethea,
E-mail: cbethea3@jhmi.edu
Tel: 410-550-4390

Principal Investigator: Phil Seo, MD, MHS

St. Joseph's Healthcare, Hamilton, ON

Study Coordinator: Sandra Messier,
E-mail: smessier@stjoes.ca
Tel: 905-522-1155 Ext. 35873
Principal Investigator: Nader Khalidi, MD

Mount Sinai Hospital, Toronto, ON

Study Coordinator: Julia Farquharson,
E-mail: jfarquharson@mtsinai.on.ca
Tel: 416-586-8616
Principal Investigator: Simon Carette, MD

**University of Pittsburgh,
Pittsburgh, Pennsylvania**

Study Coordinator: Dawn McBride
E-mail: dlmc@pitt.edu
Tel: 412-586-3545

Principal Investigator:
Kathleen Maksimowicz-McKinnon, DO

University of Utah, Salt Lake City, Utah

Study Coordinator: Julieanne Nielsen
E-mail: Julieanne.Nielsen@hsc.utah.edu
Tel: 801-585-0798

Principal Investigator: Curry Koenig, MD, MS